Osteoporosis: Epidemiology and treatment;L'ostéoporose: Épidémiologie, clinique et approches thérapeutiques

Medecine/Sciences

Volumn 17, Issue 12, 2001, Pages 1297-1305

  Fontana, A ^a   Delmas, P D ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PARATHYROID HORMONE; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BONE DENSITY; BONE DISEASE; BONE MINERAL; DRUG EFFICACY; EXPERIENCE; FRACTURE; HORMONAL REGULATION; HORMONE SUBSTITUTION; HUMAN; OSSIFICATION; OSTEOPOROSIS; REVIEW; SUBSTITUTION THERAPY;

EID: 0035673628     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/200117121297     Document Type: Review

References (56)

1. Prophylaxis and treatment of osteoporosis
2. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis
3. Avian osteoclasts as estrogen target cells
4. How many women have osteoporosis now?
5. Hip fractures in the elderly: A world-wide projection
6. Differing patterns of osteoporosis across-the world
7. A prospective study on socioeconomic aspects on fracture of the proximal femur
8. Sex-specific and race-specific hip fractures rates
9. Decline in physical function following hip fracture
10. Epidemiology of vertebral osteoporosis
11. Incidence of clinically diagnosed vertebral fractures: A population-based study in Rochester, Minnesota, 1985-1989
12. Prevalence and incidence of vertebral deformities
13. Incidence of Colls' fractures in a north american community
14. Epidemiology of osteoporosis
15. Genetic determinants of bone mass in adults
16. Racial differences in hip axis lengths might explain racial differences in rates of hip fracture
17. Risk factors for hip fracture in European women: The MEDOS study
18. Pre-existing fractures and bone mass predict vertebral fracture incidence in women
19. Spine fracture risk is predicted by non-spine fractures
20. The use of biochemical markers of bone turnover in osteoporosis
21. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment
22. Biochemical markers of bone turnover predict postmenopausal forearm bone loss over 4 years: The OFELY study
23. Ultrasonographic heel measurements to predict hip fracture in elderly women: The EPIDOS prospective study
24. The diagnosis of osteoporosis
25. The predictive value of bone loss for fragility, fractures in women: A longitudinal study over 15 years
26. Axial and appendicular bone density predict fractures in older women
27. Bone density at various sites for prediction of hip fractures
28. Monitoring estrogen replacement therapy and identifying rapid bone losers with an immunoassay for deoxypyridinoline
29. Estrogen replacement therapy and fractures in older women
30. Treatment of postmenopausal osteoporosis with transdermal estrogen
31. The effect of postmenopausal estrogen therapy on bone-density in elderly women
32. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer
33. Bisphosphonates: A review of their pharmacokinetic properties
34. Nitrogen-containing bisphosphonates inibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras
35. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis
36. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis
37. Randomized trial of effect of alendronate on risk fracture in women with existing vertebral fractures
38. Effect of alendronate on risk fracture in women with low bone density but without vertebral fracture
39. Multinational, placebo-controlled, randomised trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study
40. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age
41. Effects of risedronate treatment vertebral and non vertebral fractures in women with postmenopausal osteoporosis. A randomised controlled trial
42. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
43. Effect of risedronate on the risk of hip fracture in elderly women
44. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absoptiometry in healthy premenopausal and postmenopausal women
45. The effects of raloxifene on bone mineral density, serum cholesterol, and uterine endometrium in postmenopausal women
46. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: Three-year data from 2 doubleblind, randomized, placebo-controlled trials
47. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial
48. The effect of raloxifene on risk of breast cancer in postmenopausal women
49. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the more trial. Multiples outcome of raloxifène evolution
50. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women
51. Fluoride salt are no better at preventing new vertebral fractures than calcium-vitamin D in post-menopausal osteoporosis: The FAVOS study
52. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study
53. Use of statins and risk of fractures
54. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
55. Sex differences in age-related channges in vertebral body size, density and biochemical competence in normal individuals
56. Alendronate for the treatment of osteoporosis in men